STOCK TITAN

CTI BioPharma to Present at the 20th Annual Needham Virtual Healthcare Conference on Wednesday, Apr. 14

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

SEATTLE, April 7, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at the 20th Annual Needham Virtual Healthcare Conference at 3:00 p.m. EST. The conference will be held in a virtual meeting format.

Presentation details:

Event: 20th Annual Needham Virtual Healthcare Conference
Date: Wednesday, April 14, 2021
Time: 3:00 p.m. EST

The presentation will be webcast live and available for replay from the Investors section of CTI BioPharma's website at www.ctibiopharma.com.

About CTI BioPharma Corp.

We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. In addition, we have recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in Seattle, Washington.

CTI BioPharma Investor Contacts:

Maghan Meyers

+212-600-1902

cti@argotpartners.com

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-to-present-at-the-20th-annual-needham-virtual-healthcare-conference-on-wednesday-apr-14-301263743.html

SOURCE CTI BioPharma Corp.

CTIC

NASDAQ:CTIC

CTIC Rankings

CTIC Latest News

CTIC Stock Data

1.20B
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Seattle

About CTIC

cti was founded on the belief that a coalition between unique scientific technology and its strong desire to “do right” by the patient could help us achieve our mission to acquire, develop and bring to market less toxic, more effective therapies to treat and cure cancer. we strive to do business better than other biopharmaceutical companies. better means a more collaborative, well-trained team environment willing to institute novel approaches to scientific discovery and business opportunities. a willingness to push the limits to achieve challenging goals is the essential attribute that sets cti employees apart.